Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2007
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
A Keshaviah, S Dellapasqua, N Rotmensz, et al.
British Journal of Cancer
|
November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
J Bernhard, D Zahrieh, J J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2011
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX
S Aebi, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
P Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M Rabaglio, Z Sun, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2008
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
G Gruber, B F Cole, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group
G Marini, S Murray, A Goldhirsch, et al.
British Journal of Cancer
|
November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
J Bernhard, D Zahrieh, A S Coates, et al.
Breast Cancer Research and Treatment
|
December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
J Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
M Colleoni, S Li, R D Gelber, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2007
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
A Keshaviah, S Dellapasqua, N Rotmensz, et al.
British Journal of Cancer
|
November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
J Bernhard, D Zahrieh, J J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2011
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX
S Aebi, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
P Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M Rabaglio, Z Sun, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2008
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
G Gruber, B F Cole, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group
G Marini, S Murray, A Goldhirsch, et al.
British Journal of Cancer
|
November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
J Bernhard, D Zahrieh, A S Coates, et al.
Breast Cancer Research and Treatment
|
December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
J Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
M Colleoni, S Li, R D Gelber, et al.
Page
of 4